title: Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
abstract: OBJECTIVE
  Intrapleural cisplatin-based chemotherapy has been used in the treatment of patients with malignant pleural mesothelioma and malignant pleural effusions, but the pharmacokinetics of this form of chemotherapy have not been previously evaluated. We performed pharmacokinetic studies on 12 patients who received both intrapleural cisplatin and mitomycin immediately following pleurectomy/decortication for malignant pleural mesothelioma.
  
  
  METHODS
  Simultaneous pleural fluid and plasma samples were collected at 15 and 30 minutes, and at 1, 2, 3, 4, and 24 hours after administration of the intrapleural chemotherapy (cisplatin 100 mg/m2 and mitomycin 8 mg/m2), and after cisplatin (total and free) and mitomycin levels were measured. The mean peak levels, the areas under the concentration-time curve (AUC) and the drug half-lives (t1/2s) in plasma and pleural fluid were compared using the paired t test. Differences were considered significant if P less than or equal to .05.
  
  
  RESULTS
  Systemic absorption was rapid, with peak plasma levels being reached within 1 hour of administration of the intrapleural chemotherapy. Peak plasma levels measured after intrapleural chemotherapy approximated those reportedly attained during systemic administration of these drugs at similar doses. However, the mean peak cisplatin and mitomycin levels, and their mean AUCs, were significantly higher in the pleural fluid than in the plasma. There was a three- to fivefold advantage (on a logarithmic scale) for pleural to plasma AUCs for both cisplatin and mitomycin. The mean t1/2s for cisplatin and mitomycin were significantly longer in the plasma than in the pleural fluid.
  
  
  CONCLUSIONS
  The pharmacokinetics of intrapleural cisplatin-based chemotherapy are analogous to those of intraperitoneal chemotherapy. Our findings show that intrapleural cisplatin-based chemotherapy has a distinct local pharmacologic advantage, but also produces significant and sustained drug plasma levels.
authors.affiliation: Thoracic Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
authors.forename: V W
authors.initials: VW
authors.lastname: Rusch
authors.forename: D
authors.initials: D
authors.lastname: Niedzwiecki
authors.forename: Y
authors.initials: Y
authors.lastname: Tao
authors.forename: C
authors.initials: C
authors.lastname: Menendez-Botet
authors.forename: A
authors.initials: A
authors.lastname: Dnistrian
authors.forename: D
authors.initials: D
authors.lastname: Kelsen
authors.forename: L
authors.initials: L
authors.lastname: Saltz
authors.forename: M
authors.initials: M
authors.lastname: Markman
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D006801:Humans; D007322:Instillation, Drug; D008654:Mesothelioma / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D008937:Mitomycins / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010994:Pleura / Q000601:surgery; D016066:Pleural Effusion, Malignant / Q000378:metabolism; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D011446:Prospective Studies
chemical_list: D008937:Mitomycins; D002945:Cisplatin